Offer - Urjas Oil for just ₹ 1 X
Maball is a prescription drug, available for use as Injection. It is typically used for the treatment of Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia. Maball also has some secondary and off-label uses. These are listed below.
Medical history of the patient along with age and gender determines the dosage of Maball. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
Maball also has some side effects, the most common being Weakness. While these are the most often observed Maball side effects, there are can be others also. These have been listed below. Usually, these side effects of Maball go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
It is also important to note that Maball has a Moderate effect for pregnant women and Severe effect on lactating mothers. Warnings related to Maball's effects on the liver, heart and kidney, if any, have been listed below.
Maball can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Maball in conditions like Hyperkalemia. Other contraindications of Maball have been discussed in the sections ahead.
Drug reaction of Maball with other medicines has been reported. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Maball is considered not safe while driving, and is not addictive.
Maball is used to treat the following -
Other Benefits
Maball should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Maball unless your doctor advises you to do so -
Is this Maball habit forming or addictive?
Maball is not addictive in nature.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Rituxan (rituximab)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1106-1109
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 872